© Reuters. FILE PHOTO: A woman holds test tube in front of displayed Bristol Myers Squibb logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo/File Photo
(Corrects to add dropped word in headline)
(Reuters) – Bristol Myers (NYSE:) Squibb said on Friday it would acquire Turning Point Therapeutics (NASDAQ:) Inc for $4.1 billion in cash to gain access to its experimental cancer drug.
(The story corrects to add dropped word in headline.)
Be the first to comment